mental therapeutics (including clinical trials); disease prevention; health promotion; behavioral sciences; health services research; treatment eff ectiveness research; and health economics. Translational research refers to research that moves across boundaries and has been traditionally defi ned as "bench-tobedside" research, in which fi ndings from the laboratory are applied to research subjects. More broadly defi ned, translational research represents a variety of studies that move across traditional boundaries; for example, from the laboratory to the clinic, or the reverse; from medical center patients to the community; or from epidemiology to health policy.
For research that involves patients or healthy control individuals, clinical investigators are the crucial fi nal link between research and clinical care. Clinical investigators have knowledge and experience in dealing with medical conditions and wellness, but they also need expertise and skill sets related to the discipline of clinical investigation (Table 1) . Th e diff erence between the expert clinician and the clinical investigator was recognized by the U.S. National Institutes of Health (NIH) when it created the Clinical and Translational Science Award (CTSA) program, which includes postdoctoral career development for clinical investigators. Indeed, one of the main reasons why NIH launched the CTSA program in 2006 was to spur the development of clinical investigation into a distinct career specialization that crosses professional and medical disciplines (2).
Clinical research is the engine that drives progress in medical practice, and a vigorous and eff ective clinical research enterprise is a necessary prerequisite for better understanding of health and disease and for effective application of the rapidly expanding knowledge bases in the biomedical and social sciences to human populations. Th us it seems self-evident that the health and well-being of our nation critically depend on the vitality of our clinical research enterprise. At a time when the United States is expending more than $2.4 trillion per year on health care, expenditures are rising rapidly, and the nation is contemplating changes to the health care system, it is essential that we include a vision for a strong clinical research enterprise as a major component in our planning. Th ese fi ndings suggest a systemic imbalance in funding for physicians proposing clinical research projects. As a result, many well-trained clinical investigators leave the research fi eld for clinical practice or to enter industry.
CHALLENGES FACING THE CLINICAL INVESTIGATOR
Additional factors thought to threaten the clinical research workforce include a dearth of clinical research mentors, everincreasing clinical demands, signifi cant debt aft er fi nishing medical school, an ever more complex regulatory environment, concerns about confl icts related to the relationship between academic investigators and industry, and loss of talent to the pharmaceutical industry.
THE RESPONSE AND OPPORTUNITIES CREATED
Much of the response to concerns about the clinical investigator has focused on building the clinical research workforce. New initiatives include the physician loan repayment program, which partially alleviates an economic disincentive for physicians to enter research careers (6) In parallel to the growth of the clinical research workforce, knowledge has exploded in genetics, imaging, systems biology, bioengineering, nanotechnology, and many other fi elds. Electronic health record technology (10) is developing rapidly, and the interface with electronic research records will not be far behind. A comparative eff ectiveness agenda has begun to emerge that the federal government has recognized as being key to both improving the nation's health and reforming health care: $1.1 billion was authorized for comparative eff ectiveness research as part of the American Recovery and Reinvestment Act. Comparative eff ectiveness research is badly needed. Patients commonly receive expensive tests and treatments despite a lack of data that show the value of the test or treatment. On the other hand, commercial 
insurance oft en rejects coverage for educational programs or other multidisciplinary treatment approaches simply because data demonstrating eff ectiveness are not available. Clinical research is the only way to answer questions of eff ectiveness. Some have called for a new clinical research science that is aimed at defi ning "value" in health care (11) .
Th e programs described above have resulted in an emerging workforce fully capable of addressing the crucial questions of eff ectiveness and value and of introducing new knowledge and technologies into medical practice, but major barriers remain to implementing such developments to improve the public health.
WHAT ARE THE BARRIERS?
Despite the opportunities and urgent need for a robust national clinical research enterprise, this endeavor is threatened for two reasons. First, there is no stable career path for the clinical investigator within our teaching hospitals and medical schools. Th e appointment, promotion, and tenure systems recognize and reward individual scientists who conduct basic biomedical research in preference to team-based clinical investigators, and there is no defi ned career track with secure funding for the clinical investigator within the health care system itself. Clinical investigators must meet the challenge of seeking funding for clinical research, project by project, while simultaneously navigating the numerous complex systems related to clinical research. Th e funding challenges for clinical investigators have been discussed repeatedly, but no proposed solutions have been implemented. Second, the clinical research enterprise and the clinical care enterprise have evolved along largely separate pathways and are consequently disconnected at numerous levels, creating near-insurmountable obstacles for the clinical investigator. We have developed separate accreditation mechanisms, human protection mechanisms, medical and research record systems, adverse and sentinel event reporting methods, compliance offi ces, billing offi ces, contracting offi ces, and fi nancing structures (Table  2) . Th e result is that we have two completely separate enterprises. Th is is unfortunate, because the patients are the same people as the research subjects, the health care professionals are the clinical investigators, and clinical and research visits oft en occur at the same time and in the same room, but the clinical and research visit "events" are completely separated at multiple levels administratively and procedurally.
Academic medical centers have dealt with this problem by creating separate research offi ces, which generally have little to do with hospital or medical practice administrative offi ces. Some have segregated clinical research to research units within hospitals or to separate fl oors or research buildings. Th e clinical investigator can be bewildered by two separate sets of rules and regulations, two separate sets of administrative offi ces, and minimal administrative help on the clinical research side.
Th ere is little doubt that just navigating the byzantine interface of the clinical research administrative infrastructure discourages those seeking a career in the fi eld. Not only does the clinical investigator have to dedicate increasing amounts of time to funding his or her research career while also meeting increased patient care demands, but the investigator must also devote tremendous amounts of time to addressing the administrative maze of the clinical research and patient care structures.
A RADICAL PROPOSAL
We need a national plan in the United States to eff ectively integrate the enterprises of clinical research and patient care at every level. Integration could minimize or even eliminate a major disincentive for those who want to pursue a career in research. Clinical investigators must become central to the mission of health care, and we must create a culture of analysis and continuous improvement. We need a new model in health care-one that is much more effi cient and eff ective and is constantly evolving based on evidence that is produced by the system itself. We need continuous introduction of incremental and innovative treatments, powered by data concerning the delivery systems, insurance coverage methods, eff ectiveness, and costs and benefi ts of care. Th is can only be accomplished by establishing an attractive career for clinical investigators within the health care system and by integrating research and care at the fi nancing, regulatory, and administrative levels. Th e 
two systems cannot operate eff ectively as two separate worlds, because the quality of care provided by the U.S. health care system critically depends on the health and vitality of U.S. clinical research, and vice versa.
Th is fundamental problem has received almost no discussion, although some have alluded to it. Th e AAMC Task Force I on Clinical Research stressed that "clinical research lies at the interface of the medical school and its affi liated clinical delivery system" and emphasized how academic health systems must have a strategic plan for integrating clinical investigation into the medical education and health care delivery enterprises, noting that the organizational complexity of health care systems is a barrier that has to be overcome (12) . For the most part, such integration has not occurred.
Horig et al. (13) recommended "radical change in the practice of health care delivery … so that the public can benefi t from modern, interactive and educated approaches to personalized health care, " but did not specify what the radical changes might be. Others have suggested national bodies for biomedical research policy and the promotion of clinical and translational investigation and, in particular, new funding strategies (13) (14) (15) (16) (17) . However, these eff orts principally address investigator-funding issues and do not address the need to integrate clinical research with the health care system. Crowley et al. suggested that 0.25% of the budgets from health care stakeholders would be adequate to support a public/ private partnership-the National Clinical Research Enterprise-and would enable the creation of the national infrastructure needed to transform clinical research into a national enterprise that would serve the public health (14) . Th is idea comes closest to a mechanism to integrate clinical research with the health care system.
We propose that the U.S. Congress commission the Institute of Medicine to study the issue of clinical research and health care integration and make specifi c recommendations. Th ese directives should include approaches to harmonizing the regulatory environments, creating a fi nancing system for investigators, and developing methods for setting research priorities and funding high-priority projects. Without radical change leading to eff ective integration, clinical investigators will continue to struggle, and opportunities to improve human health will go unfulfi lled. Indeed, clinical research may remain "a fragmented cottage industry … with no overarching vision, no cohesive organizational framework, and at times not even a common forum for dialogue or active collaboration" (14) . Eff ective integration and fi nancing can position the U.S. clinical research enterprise to serve the health needs of the public by providing a rapid mechanism for the application of new knowledge and technology to human populations, and for the gathering of evidence on which to base crucial decisions about the eff ectiveness of health care interventions, health care delivery systems, and the myriad medical services currently available.
